Silence Therapeutics (SLN) Projected to Post Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Silence Therapeutics to announce earnings of ($0.1129) per share and revenue of $0.11 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 2:00 AM ET.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. On average, analysts expect Silence Therapeutics to post ($0.82) EPS for the current fiscal year and ($0.94) EPS for the next fiscal year.

Silence Therapeutics Stock Up 0.1%

Shares of NASDAQ SLN opened at $19.78 on Wednesday. The firm has a market cap of $1.19 billion, a P/E ratio of -15.45 and a beta of 1.34. Silence Therapeutics has a twelve month low of $4.19 and a twelve month high of $19.86. The company has a 50 day moving average of $13.74 and a 200 day moving average of $9.18.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. HC Wainwright lowered Silence Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $75.00 to $20.00 in a report on Wednesday, October 21st. Chardan Capital cut Silence Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Morgan Stanley upped their price target on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Jefferies Financial Group cut Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price objective on the stock. in a research report on Monday, October 19th. Finally, William Blair downgraded Silence Therapeutics from an “outperform” rating to a “hold” rating in a report on Monday, October 19th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $24.00.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its approach is designed to intervene at the genetic messenger RNA stage, potentially providing targeted and durable effects for patients with serious diseases.

The company’s proprietary mRNAi GOLD platform supports the design and delivery of siRNA medicines, including compounds intended to target tissues such as the liver.